Search

Search results

4256 results found

Health Care Policy Research Section takes on AcademyHealth Annual Research Meeting 2025

Page

At the beginning of the month, nine members of the Health Care Policy Research Section heading over to Minneapolis to give a total of twelve presentations at the four-day national health policy conference. Covering a variety of health policy topics, our work was featured in sessions on Medicaid...

Lifetime Health and Economic Outcomes of Biparametric Magnetic Resonance Imaging as First-Line Screening for Prostate Cancer : A Decision Model Analysis

Publication: Bill

Gulati, R., B. Jiao, R. Al-Faouri, V. Sharma, S. Kaul, A. Fleishman, K. Wymer, et al. 2024. Lifetime Health and Economic Outcomes of Biparametric Magnetic Resonance Imaging As First-Line Screening for Prostate Cancer : A Decision Model Analysis.

Predicting cancer detection rates from multiparametric prostate MRI Beyond the PI-RADS classification system

Publication: Bill

Perez-Londono, A., F. Ramos, A. Fleishman, S. Kaul, R. Korets, M. Johnson, A. F. Olumi, L. Tsai, and B. Gershman. 2025. Predicting Cancer Detection Rates from Multiparametric Prostate MRI Beyond the PI-RADS Classification System.

Extended prostate needle biopsy improves concordance of Gleason grading between prostate needle biopsy and radical prostatectomy

Publication: Bill

San Francisco, I. F., W. C. DeWolf, S. Rosen, M. Upton, and A. F. Olumi. 2003. Extended Prostate Needle Biopsy Improves Concordance of Gleason Grading Between Prostate Needle Biopsy and Radical Prostatectomy.

Pathologic quiz case. A symptomatic renal tumor. Juxtaglomerular cell tumor

Publication: Bill

Kuten, A., A. Olumi, J. Goldsmith, R. A. Monahan-Earley, A. M. Dvorak, and E. M. Genega. 2004. Pathologic Quiz Case. A Symptomatic Renal Tumor. Juxtaglomerular Cell Tumor.

Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen

Publication: Bill

San Francisco, I. F., M. M. Regan, A. F. Olumi, and W. C. DeWolf. 2004. Percent of Cores Positive for Cancer Is a Better Preoperative Predictor of Cancer Recurrence After Radical Prostatectomy Than Prostate Specific Antigen.

Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer

Publication: Bill

Zhang, X., T. G. Jin, H. Yang, W. C. DeWolf, R. Khosravi-Far, and A. F. Olumi. 2004. Persistent C-FLIP(L) Expression Is Necessary and Sufficient to Maintain Resistance to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Apoptosis in Prostate Cancer.

Surgical management of scrotal lymphedema using local flaps

Publication: Bill

Halperin, T. J., S. A. Slavin, A. F. Olumi, and L. J. Borud. 2007. Surgical Management of Scrotal Lymphedema Using Local Flaps.

MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L)

Publication: Bill

Li, W., X. Zhang, and A. F. Olumi. 2007. MG-132 Sensitizes TRAIL-Resistant Prostate Cancer Cells by Activating C-Fos/C-Jun Heterodimers and Repressing C-FLIP(L).

Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model

Publication: Bill

Zhang, L., X. Zhang, G. W. Barrisford, and A. F. Olumi. 2007. Lexatumumab (TRAIL-Receptor 2 MAb) Induces Expression of DR5 and Promotes Apoptosis in Primary and Metastatic Renal Cell Carcinoma in a Mouse Orthotopic Model.